

www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

## Recombinant SARS-Cov-2 Spike S1 protein (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y), His (HEK293)

Catalog Number:	bs-43042P
Concentration:	>0.5 mg/ml
AA Seq:	14-685/1273
Predicted MW:	73
Detected MW:	120-140 kDa
Tags:	His
Activity:	Yes
Endotoxin:	Not analyzed
Purity:	>90% as determined by SDS-PAGE
Purification:	AC
Form:	Lyophilized or Liquid
Storage:	PBS (pH7.4).
	Stored at -70°C or -20°C. Avoid repeated freeze/thaw cycles.
Background:	The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19
	pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein
	appeared early during the pandemic, and are now the dominant form worldwide. Here, we
	analyze the D614G mutation in the context of a soluble S ectodomain construct.

## VALIDATION IMAGES





The purity of the protein is greater than 90% as determined by reducing SDS-PAGE.

The purity of the protein is greater than 90% as determined by reducing SDS-PAGE.

## PRODUCT SPECIFIC PUBLICATIONS

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

**[IF=15.1]** Feiyun Cui. et al. GlycoEVLR: Glycosylated extracellular vesicle-like receptors for targeting and sensing viral antigen. CHEM ENG J. 2023 Aug;469:143844 Other ; . 10.1016/j.cej.2023.143844